icon-folder.gif   Conference Reports for NATAP  
 
  ID Week
October 2-6, 2013
San Francisco
Back grey_arrow_rt.gif
 
 
 
Interim Analysis of an Interferon (IFN)- and Ribavirin (RBV)-Free Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 in Treatment-Naive, Hepatitis C Virus Genotype 1-Infected Patients
 
 
  Reported by Jules Levin
IDSA Oct 2-6 2013 San Francisco, CA
 
Gregory T. Everson*1, Karen D. Sims2, Maribel Rodriguez-Torres3, Christophe Hezode4,
Eric Lawitz5, Marc Bourliere6, Veronique Loustaud-Ratti7, Vinod Rustgi8, Howard Schwartz9, Harvey Tatum10, Patrick Marcellin11, Stanislas Pol12, Paul J. Thuluvath13, Timothy Eley2, Xiaodong Wang2, Shu-Pang Huang14, Fiona McPhee15, Megan Wind-Rotolo14, Ellen Chung2, Claudio Pasquinelli2, Dennis M. Grasela2, David F. Gardiner2
1University of Colorado Denver, Aurora, CO, USA; 2Bristol-Myers Squibb, Hopewell, NJ, USA; 3Fundacion de Investigacion, San Juan, Puerto Rico; 4CHU Henri Mondor, Service d'Hepato-Gastroenterologie, Creteil, France; 5Alamo Medical Research, San Antonio, TX, USA; 6H˘pital Saint Joseph, Service d'Hepato-Gastroenterologie, Marseille, France; 7University Hospital of Limoges, Limoges, France; 8Metropolitan Research, Arlington, VA, USA; 9Miami Research Associates, South Miami, FL, USA; 10Options Health Research, Tulsa, OK, USA; 11H˘pital Beaujon, Clichy, France; 12Universite Paris Descartes, INSERM U1610 and Liver Unit, H˘pital Cochin, Paris, France; 13Mercy Medical Center, Baltimore, MD, USA; 14Bristol-Myers Squibb, Princeton, NJ, USA; 15Bristol-Myers Squibb, Wallingford, CT, USA

ID1.gif

ID2.gif

ID3.gif

ID4.gif

ID5.gif

ID6.gif

ID7.gif

ID8.gif

ID9.gif

ID10.gif

ID11.gif

ID12.gif